Software & Data
San Jose, CA
Overall Rank: 45
Category: Software & Data
Category Rank: 13
- Top HealthTech Company of 2023
BrightInsight, founded in 2017, provides the leading global platform for compliant biopharma and medtech digital health solutions, helping companies accelerate time-to-market for digital health offerings across therapeutic areas, including drug companion apps, healthcare provider interfaces, analytics dashboards, algorithms, medical devices, connected combination products, diagnostics and Software as a Medical Device (SaMD).
The BrightInsight® Platform replaces the need for lengthy and complex “build from scratch” implementations by offering configurable software solutions and a proven platform built under a Quality Management System to support global security, privacy and regulatory requirements. BrightInsight has more than 200 employees in the U.S., Europe and India, and its platform is available across 64 geographies. Its customers include some of the world’s leading biopharma and medtech companies, such as CSL Behring, Roche, and bioMérieux.
The Disease Management Solution, built on top of the compliant BrightInsight Platform, is a configurable suite of digital applications including a Patient App, Analytics Dashboards, and Healthcare Provider Interfaces, with mobile and data analytics capabilities that enable customers to rapidly build, configure, localize, and optimize patient companion apps at scale, in a more cost-effective manner. The platform now supports NFC- and Bluetooth-enabled medical device integrations across several device types, such as blood pressure, blood glucose, heart rate, weight, and temperature monitors. Patient apps built on the BrightInsight Platform can also integrate seamlessly with Apple Health and Google Fit, as well as map and weather apps, and is interoperable through FHIR standards with Electronic Health Records (EHR) and Laboratory Information Systems (LIS). To further enable ongoing app optimization, BrightInsight built out a robust data engine that enables biopharma companies to export and analyze app utilization, engagement, and more, while meeting stringent privacy requirements.
Disease Management Solution
BrightInsight’s Disease Management Solution is a suite of software tools and services designed to help biopharma and medtech companies improve patient outcomes and manage chronic diseases. The solution includes a patient app, healthcare provider interfaces, and analytics dashboards. The patient app offers patient-centered tools to inform and engage, with the goal of improving outcomes.
The healthcare provider interfaces enable clinicians to see trend data directly within their EHR workflow to track how their patients are responding to therapy. The analytics dashboards provide actionable insights into patient behavior and outcomes.
Software as a Medical Device (SaMD) Solutions
Software as a Medical Device (SaMD) is software that is intended to be used for one or more medical purposes that doesn’t require a hardware medical device. SaMD solutions can be used for a variety of purposes, including educating patients about their condition, tracking and adjusting dosing, increasing adherence, managing chronic diseases, and more.
SaMD is the backbone of next-generation companion apps, dosing and treatment selection algorithms, data analytics and more. The top five pharmaceutical companies invested a combined $270 million in SaMD initiatives between January 2019 and October 2021. Disease management is the most cited use case for SaMD solutions. BrightInsight is the industry leader in SaMD development and has brought 14 SaMDs to market to date, with more in development. Biopharma and medtech companies trust BrightInsight’s compliant platform to differentiate and expand the value of their therapies with groundbreaking digital solutions.
Connected Diagnostics Platform
BrightInsight’s Connected Diagnostics Platform can help IVD companies transform device management from reactive to proactive. With the platform, companies can use real-time data to streamline workflows, accelerate revenue growth, and drive portfolio innovation. The Connected Diagnostics Platform is four powerful tools in one, and includes a Proxy Agent, Analytics Dashboards, Integration Middleware and Workflow Portals (for the IVD manufacturer and the Lab), all running on the compliant and secure BrightInsight Platform. BrightInsight eliminates the need for multiple products and partners, enabling accelerated time to market and minimizing risk with our best-in-class cybersecurity, privacy compliance and global scalability. The Connected Diagnostics Platform enables consistent clinical workflows, while reducing costs and increasing visibility into device utilization. Additionally, BrightInsight’s platform can help you optimize device performance and drive revenue with Real-World Data.
BrightInsight, with its unwavering dedication to fostering innovation and driving impactful change, receives heartfelt appreciation and commendation from diverse stakeholders in the fields of life sciences, healthcare, and technology. It is a leading provider of digital health solutions for biopharma and medtech companies. The company’s platform helps customers accelerate clinical trials, improve patient engagement, and bring new therapies to market faster.
BrightInsight has received positive feedback from its customers, who appreciate the company’s commitment to innovation and its focus on providing solutions that meet the specific needs of the biopharma and medtech industries. Patients, clients, and partners in the life science and healthcare industries laud BrightInsight’s commitment to advancing transformative technologies and cutting-edge research.
“After conducting a rigorous evaluation, we selected BrightInsight because it was the only regulated solution with a robust Quality Management System and comprehensive privacy and security certifications. BrightInsight’s Platform allows us to focus on therapeutic innovation, rather than the underlying digital technology. CSL Behring is committed to delivering on our promise to support and empower our patients through digital engagement, and the Hizentra app is a step towards providing more holistic treatment experiences,” said one digital leader of a leading biopharma company.
The company’s commitment to regulatory compliance has instilled trust in its biopharma customers. Moreover, customers have commended BrightInsight’s dedication to enhancing the patient experience.
- Founded: 2017
- Number of employees: 200+
- Locations: employees in US, UK, Ireland, the Netherlands, France, Spain, Switzerland, Colombia and India
- Capital raised from investments: $180M+
- No of deployment-ready countries: 64
- Healthcare organization integrations supported: 1700+
Rating and Commentary
BrightInsight’s exceptional leadership team is at the forefront of driving innovation and fostering transformative change in the life sciences, healthcare, and technology sectors. Led by the CEO and Co-Founder, Kal Patel, MD,, with a wealth of experience and expertise, the organization has demonstrated a strong commitment to innovation and customer-centric solutions. Their unwavering dedication to advancing cutting-edge digital solutions has positioned BrightInsight as a key driver of positive impact.
Backed by top healthcare and tech investors, BrightInsight is poised for continued growth and success. With renowned venture capital firms and corporate partners, like General Catalyst and Insight Partners in its corner, the company enjoys access to a wide range of resources and expertise. These investors not only provide crucial financial support but also offer invaluable guidance and mentorship to startups and entrepreneurs.
While there may be other organizations competing in this space BrightInsight stands out from the competition with its robust investment in its platform technology, experience across healthcare domains, and its privacy, security, and regulatory acumen. The company’s strong partnerships with leading biopharma, medtech and technology organizations and industry leaders have enabled it to build a robust innovation ecosystem that fosters breakthrough solutions. The company’s strategic approach and partnerships have helped it to grow its reach and expand into new markets. This has provided a solid foundation for future growth.
The company’s strong leadership and innovative culture have helped it to establish itself as a trusted and preferred choice in the healthcare industry.
Kal Patel, MD, CEO and Co-Founder
Kal Patel, MD is a seasoned healthcare executive with over 20 years of experience in pharma, medtech, and regulated digital health. Prior to founding BrightInsight, Kal was the chief commercial officer of Doctor on Demand, a leading video-medicine provider. He also founded and built Amgen’s Digital Health business unit, where he had end-to-end responsibility for developing and commercializing a portfolio of regulated digital products. Prior to his focus on digital health at Amgen, Kal was the Global Marketing Lead for Enbrel, the company’s leading drug with over $6B in sales, where he created and launched major investments in novel clinical trials, innovative drug delivery devices, improved formulations and differentiated patient support programs. Kal started his Amgen career as Head of Corporate Strategy. He was previously Senior Advisor in Digital Health for the Boston Consulting Group , where he worked with a broad portfolio of healthcare companies across the U.S. and Europe.
David Matthews, PhD, Chief Growth Officer
David Matthews is a biopharma and medical technology expert with over 15 years of experience. He has held leadership positions at Boston Consulting Group and BrightInsight, where he has advised clients on strategy, commercial, R&D, and regulatory affairs. He is also a computational neuroscientist with a PhD from the University of California, San Diego. He has published over 20 publications and proceedings on machine learning, bioinformatics, brain imaging, neuroanatomy, and health economics. He has also consulted independently on machine learning applications in biomedicine, built an early telemedicine app for automated melanoma detection, and taught neuroscience as an Adjunct Professor.
Jamie Eisinger Burgess, Senior VP Marketing
Jamie is a marketing leader with over a decade of experience in the digital health industry. She has a deep understanding of the B2B enterprise software market and has a proven track record of success in developing and executing go-to-market strategies, product marketing campaigns, and demand generation programs. Prior to BrightInsight, Jamie was one of the founding members of Qualcomm Life, Inc. where she helped grow the company from its initial launch to its position as a global leader in the digital health industry. She led global marketing efforts for the Capsule product portfolio for hospitals and health systems, and for the 2net remote care solutions for leading biopharma and medtech companies.
Ashish Agrawal, Chief Technology Officer
Ashish Agrawal heads the engineering division at BrightInsight, where he has led the development of a top-tier, regulated digital health platform. His team creates and launches configurable healthcare applications tailored for BrightInsight’s biopharma and medtech customers. This encompasses various aspects such as architecture, software development, testing, security, devops, and cloud operations, including deployment and monitoring. His experience includes overseeing platform, application, and mobile development teams working in CRM, content management, asset performance management with IoT, and field service management.
Ferry Tamtoro, Co-Founder
Ferry Tamtoro co-founded BrightInsight and continues to lead the organization in technology, quality and regulatory affairs. Ferry Tamtoro has over 18 years of experience in healthcare technology and digital health within the pharmaceutical and medical devices industries. Ferry has launched multiple digital health solutions, including Class 1, 2, and 3 regulated devices and combination products. Ferry also serves as an advisor to the PDA Combination Products Task Force, alongside other leading biopharma executives. Ferry holds an MBA from Kellogg School of Management and a BS in Electrical Engineering from University of Wisconsin-Madison. He holds four patents in healthcare technology.
Caroline Peel, VP, Global Head of Sales
As Global Head of Sales, Caroline is an innovative pioneer advancing the sales business unit growth and market leadership. In her role, Caroline focuses on enterprise solutions for both biopharma and medtech to help life sciences organizations enhance patient centricity and outcomes. With 20 years’ experience in sales, strong technology software experience, and a passion for innovation, Caroline helps businesses solve the toughest challenges. Caroline’s team focuses on customers, acting as trusted advisors to ensure BrightInsight provides the highest level of service from ideation and design to bringing solutions to market. She also ensures that we successfully serve our customers in maintaining their products and scaling them globally.
According to Glassdoor, BrightInsight has an overall rating of 4.3 out of 5 stars, based on over 45 reviews. The company has a 94% approval rating from employees, and 96% of employees would recommend the company to a friend. They have a fast-paced, collaborative culture where employees have the opportunity to work with the world’s foremost digital health experts. The company’s culture is built on four core values: Passion for their mission and craft; Execution by accountable problem solvers; Collaboration and team before self; and Agility to rapidly adapt to changes and opportunity.
The company hosts a variety of social events, both in-person and virtual, to help employees connect with each other. Supporting growth is another key part of their culture. The company offers a variety of resources to help employees develop their skills and advance their careers. Improving collaboration is essential for success at BrightInsight. The company encourages employees to work together across teams and functions to solve problems and bring new ideas to life and also offers a variety of resources to help employees develop their skills and advance their careers. It is a diverse and inclusive company that values the contributions of all employees.
BrightInsight is a remote-first workplace, as well as a fast-paced, dynamic company where employees are encouraged to share ideas and collaborate with each other. This creates a stimulating and challenging work environment where employees can learn and grow.
In line with its commitment to employee growth and development, it also invests in professional development programs and mentorship opportunities. The organization recognizes the importance of work-life balance and offers flexible work arrangements and paid time off to promote employee wellness and satisfaction and has monthly “Mental Health Fridays,” when employees take the day off. Furthermore, the BrightInsight’s inclusive culture fosters diversity, where individuals from different backgrounds and experiences come together to contribute their unique perspectives.
Kal Patel, MD, CEO and Co-Founder
Kal Patel, MD is a seasoned healthcare executive with over 20 years of experience in pharma, medtech, and regulated digital health. Prior to founding BrightInsight, Kal was the chief commercial officer of Doctor on Demand, a leading video-medicine provider. He also founded and built Amgen’s Digital Health business unit, where he had end-to-end responsibility for developing and commercializing a portfolio of regulated digital products. Kal also served in a variety of marketing sales and account leadership roles at Enbrel and Novartis, and as a Senior Advisor in Digital Health for the Boston Consulting Group , where he worked for a broad portfolio of healthcare companies across the U.S. and Europe.
Vijay Lathi, Managing Director
Vijay Lathi has an investment focus on information convergence and diagnostics. He joined Sprout Venture Partners in 1998, and advanced to the role of Partner in 2003. Vijay was one of the founders of New Leaf in 2005. In his earlier investment endeavors, Vijay’s interests spanned various healthcare technologies, including healthcare information technology (HCIT), diagnostics, and therapeutic platforms. He was the founding investor in both Ilypsa (later acquired by Amgen) and Relypsa (RLYP). He obtained his B.S. from the Massachusetts Institute of Technology and his M.S. in Chemical Engineering, with an emphasis on applying engineering to life science technology, from Stanford University..
Justin is an investor with a deep understanding of how to turn scientific research into successful commercial operations. He is passionate about investing in companies that develop integrated solutions that are easy to use and beneficial to the end user. Justin is particularly interested in companies that are developing new approaches to complex problems in healthcare, security, and artificial intelligence. Before joining Eclipse, Justin built and led the commercial operations at Misfit, a digital health company that was acquired for more than $250 million. He also managed the commercialization efforts in the foods, fuels and chemicals areas at Synthetic Genomics (SGI), a leading synthetic biology company. At SGI, Justin’s work led to the development and commercialization of first-in-class technologies that were used by Fortune 100 food and chemical companies.
Dan Goldsmith is a highly accomplished executive renowned for his ability to nurture startups into thriving enterprises. With an extensive career spanning over two decades in software and management consulting, Dan has honed his expertise in cloud software, market growth strategies, global expansion, and verticalization, with a particular focus on the life sciences, healthcare, and education sectors. His impressive track record includes both executive roles as a CEO and senior leader, as well as contributions as a director and advisor within the boardroom. At present, Dan serves as the Co-Founder and CEO of a healthcare technology startup. He and his team are dedicated to crafting software solutions that deliver exceptional experiences, improve clinical outcomes, and boost efficiency for patients, healthcare providers, and organizations.
Peter Sobiloff joined Insight Partners as Managing Director in 1998. In his role as investor, Peter specializes in mentoring management teams to foster technological change in existing markets in order to produce greater productivity and deliver incremental value to customers. Peter has also served as President of Think Systems, an Insight portfolio company focused on supply chain management,; and as Vice President of Business Development at i2 Technologies. Prior to Insight, Peter was President of Datalogix, a vendor of enterprise application software for process manufacturers. He also held senior executive roles at Ross Systems, a provider of financial application software. Peter was part of the management teams that executed IPOs for both companies. Subsequently, as President of Datalogix, Peter led the sale of Datalogix to Oracle corporation. Peter currently serves on the board of directors at Fenergo, Duco, LeaseAccelerator, Kira Systems, Augury, ComplianceQuest, Planview, Hivebrite, Aquant, and NYMBUS.
Jennifer Samproni is the Chief Technology Officer of Flex Health Solutions. She leads the HS Engineering Design Centers globally and serves as a key executive team member. Jennifer has over 25 years of R&D experience in transforming businesses through growth and innovation, developing talent, optimizing resources, creating enterprise value for shareholders, developing new products and executing strategic initiatives. She has led engineering and scientific organizations comprising Assay Development, Advanced Technology and Processes, Operational Excellence and Systems Engineering functions within the medical device industry. She holds over 30 patents and patent applications, sits on the Board of Directors of BrightInsight and is based in Boston, Massachusetts.
Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of June 30, 2023, the firm has over $80B in regulatory assets under management. Insight Partners has invested in more than 800 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has offices in London, Tel Aviv, and Palo Alto. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO.
General Catalyst is a venture capital firm that specializes in collaborating with founders from the seed stage to long-term businesses, with a focus on fostering companies with long-term resilience. The company provides assistance to visionary entrepreneurs who are developing cutting-edge technology firms and industry-leading enterprises such as Airbnb, Gusto, HubSpot, Stripe, and many others. The General Catalyst team assists founders in the creation of exceptional companies by leveraging their extensive experience. General Catalyst has a global presence, with offices in San Francisco, Palo Alto, New York City, London, and Cambridge.
New Leaf Venture Partners
NLVP was established in 2005 when the healthcare team separated from the Sprout Group. The NLVP team has been assembled over the past two decades, and they are committed to making venture investments as well as private and public growth-stage biopharmaceutical investments. Their goal is to provide broad perspectives, decades of experience, and deep domain expertise to their investors as they navigate the complexities of the healthcare industry. Their portfolio includes 30 billion-dollar companies, 35 acquired companies, and 54 public companies. They’ve nurtured and developed remarkable companies at NLVP, all with the same goal in mind: to transform healthcare.
Eclipse Ventures is a venture capital firm focused on accelerating the digital transformation of critical industries. Since 2015, they have been assisting visionary entrepreneurs in creating outstanding enterprises that improve the efficiency, resilience, and profitability of traditional industries, with the goal of driving the Industrial Evolution. Their team is made up of former industry professionals who have extensive experience ranging from startup inception to post-IPO phases. While their typical investments range from initial concept to early-stage growth, their extensive knowledge and expertise enable them to think creatively and explore opportunities outside of their traditional scope. The company’s headquarters are in Palo Alto, California.
- BrightInsight and CSL Behring named 2023 Trailblazer Award Finalists by PM360 in August 2023.
- BrightInsight Named Leader in the Healthcare IoT Solutions Industry with Frost & Sullivan’s 2023 Global Company of the Year Award, in May 2023.
- In March 2023, BrightInsight made Forbes’ 2023 list of America’s Best Startup Employers.
- BrightInsight Named to Fierce Medtech’s 2022 Fierce 15 List in March 202
- BrightInsight Welcomed ixlayer to the BrightInsight Ecosystem to Streamline Diagnosis and Improve Therapy Matching, in Feb 2023
- BrightInsight ranks #217 on the Deloitte Technology Fast 500 List of Fastest Growing Companies
- In September 2022, BrightInsight, BioMérieux partner on digital health.
- On September 13, 2022, BrightInsight Launches the BrightInsight Ecosystem Bringing Together Leading Healthcare and Technology Companies to Revolutionize Patient Care Through Digital.
- BrightInsight launched the Disease Management Solution to enhance the patient experience in June 2022
- BrightInsight announced partnership with Sanofi in January 2022.
News and Press Releases
- CSL Behring, BrightInsight Launch Hemgenix companion app (Read)
- March 21, 2023: ixlayer Empowers BrightInsight, Curavit and Medable With Convenient Patient Health Testing Services (Read)
- March 30, 2023: How Agile Development Can Advance Digital Health In Pharma (Read)
- Sep 13, 2022: BrightInsight Selects Lyniate (now Rhapsody) to Enhance Interoperability (Read)
- Sep 27, 2022: BrightInsight Adds Xealth, Woebot Health and Claritas Rx to the BrightInsight Ecosystem (Read)
- Nov 14, 2022: BrightInsight Inks Enterprise Agreement with CSL Behring for Digital Health Solutions Across Brand Portfolio (Read)
- December 9, 2022: The CIO’s ‘Build Versus Buy’ Conundrum Is Now ‘Build Versus Build’ (Read)
BrightInsight is committed to corporate responsibility and has a number of initiatives in place to support its vision of transforming patient outcomes globally by bringing the power of digital technology to healthcare. The company’s cutting-edge technologies are laying the foundation for digital capabilities within the life sciences, worldwide. The company places great emphasis on ethical business practices and integrity. They adhere to strict regulatory and quality standards and promote transparency in all interactions with stakeholders, including partners, researchers, and entrepreneurs.
As a global leader in privacy, security, quality and regulatory compliance, BrightInsight’s best-in-class infrastructure and processes show a commitment to safeguarding sensitive information and protecting the data of individuals.